How Did Global Insurtech Funding Surge Despite Fewer Deals in Q2 2024?

August 8, 2024
How Did Global Insurtech Funding Surge Despite Fewer Deals in Q2 2024?

In a remarkable turn of events, the global insurtech funding landscape experienced a significant resurgence during the second quarter of 2024, according to Gallagher Re’s quarterly report. Despite a decrease in the overall number of deals, the sector saw the highest investment levels since the first quarter of 2023. This unexpected boost in funding highlights the investors’ rising confidence in the potential of insurtechs, arguably driven by the increasing prominence of technology such as artificial intelligence and risk origination.

The total insurtech funding surged to an impressive $1.27 billion in Q2 2024, representing a 39.7% increase from the previous quarter. This amount is noteworthy, especially considering the nearly doubled average deal size, which skyrocketed from $9.81 million in Q1 to $18.46 million in Q2. The standout contributor to this dramatic rise was Sidecar Health’s $165 million Series D round, marking the only mega-round deal of the year. These figures illuminate the growing appetite for substantial investments in the insurtech sector, contrasting sharply with the concurrent reduction in the number of deals.

Funding Trends and Investment Patterns

Shift in Deal Sizes and Numbers

One of the most striking aspects of Q2 2024 was the noticeable decline in the total number of deals, which fell by 23.4% to 82 deals—the lowest count since Q2 2020. This downward trend affected both the property & casualty (P&C) and life & health (L&H) sectors, with P&C deals dropping from 70 in Q1 to 54 in Q2, and L&H deals declining from 37 to 28. Despite this reduction, the notable increase in deal sizes suggests that investors are becoming more selective, placing larger bets on fewer but more promising companies.

The emphasis on larger investments is further evident in early-stage funding, which saw a 34.9% rise to $377.6 million. However, while the average deal sizes surged by 77.8% to $8.58 million, the number of early-stage deals decreased by 21.9% to 50. Seed-stage deals were particularly impacted, plummeting from 45 in Q1 to 29 in Q2. This pattern reveals a shift towards a more discerning investment approach, favoring insurtechs that demonstrate substantial promise and potential for growth.

Leading the Charge: AI and Risk Origination

A significant chunk of the Q2 2024 investments went to insurtechs focused on artificial intelligence (AI) and risk origination. AI insurtechs accounted for 32.9% of the deals, successfully raising $445.8 million. Interestingly, these deals featured smaller average deal sizes compared to their non-AI counterparts, a reversal from the trend witnessed in Q1. This might indicate an early-stage focus within the AI sub-sector, where smaller but more frequent investments are made to cultivate diverse innovations.

On the other hand, risk origination insurtechs captured an even larger share, constituting 40.2% of the deals and amassing a substantial $742.5 million. Most of the top funding deals were linked to risk origination companies, underscoring the sector’s critical role in attracting investor dollars. Four out of the top five funding deals were risk-focused insurtechs. These included Sidecar Health with $165 million Series D, ICEYE obtaining $93 million in Series D funding for satellite data provision, Cover Genius securing $80 million in Series E for embedded insurance, and Honey Insurance raising $71 million in Series A for homeowners’ insurance. These substantial investments highlight the robust investor interest in risk management solutions and advanced data analytics.

Market Evolution and Future Prospects

Growing Maturity of the Insurtech Market

The Q2 report signals a clear shift toward a more mature insurtech market, characterized by substantial financial growth, larger individual investments, and a lower overall deal count. Investors are increasingly prioritizing quality over quantity, focusing their resources on fewer but more promising ventures. This discerning approach is likely driven by a desire to back firms with proven innovative capabilities and substantial growth prospects, especially those leveraging advanced technologies like AI and risk analytics.

The maturation of the market is also reflected in the strategic investments in early-stage companies, where the emphasis has shifted from the mere number of deals to the potential impact of each investment. While fewer early-stage deals were closed, the significantly larger average deal sizes indicate that investors are willing to commit more resources to startups with compelling business models and scalable solutions. This trend is particularly crucial for the insurtech industry, where the ability to innovate and adapt swiftly to technological advances is paramount.

Implications for Future Investment Strategies

In a surprising development, Gallagher Re’s quarterly report reveals a significant upswing in global insurtech funding during the second quarter of 2024. Even though the total number of deals declined, investment levels reached their highest point since Q1 2023. This unexpected boost underscores investors’ growing confidence in the potential of insurtechs, likely fueled by the rising adoption of technologies like artificial intelligence and advanced risk origination.

Total insurtech funding soared to an impressive $1.27 billion in Q2 2024, marking a 39.7% increase from the previous quarter. This surge is particularly significant given the nearly doubled average deal size, which leaped from $9.81 million in Q1 to $18.46 million in Q2. A major contribution to this dramatic increase was Sidecar Health’s $165 million Series D round, the only mega-round deal of the year. These figures highlight a growing appetite for substantial investments in the insurtech sector, even as the number of deals decreases, pointing to a trend of fewer but more impactful investments.

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later